Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Vet Res Commun ; 45(4): 293-304, 2021 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-34219191

RESUMO

Wounds are damaging to quality life of confined animals, causing dysfunction in spinal, members injuries, and reduction in productive performance. This research investigated the clove antimicrobial and antioxidant activity on the healing of decubitus wounds (pododermatitis) of rabbits (Oryctolagus cuniculus). Adult animals were treated for 21 days every three days with a fluid gel spray in the wound region: control fluid gel without addition of clove (FGC0), fluid gel with addition of 1% clove powder (FGC1), and fluid gel with 2% clove powder (FGC2). Microbiological analysis for Escherichia coli and Pseudomonas spp. were performed during 21 days of experimental period. After this period, samples from treated skin were evaluated for histological analysis and evaluation of the healing process by spectroscopy (FTIR-ATR). Rabbits treated with FGC2 showed advanced healing and decreased tissue inflammation similar to healthy rabbits, while FGC0 rabbits showed a decrease in bacterial contamination without signs of healing. Both FGC1 and FGC2 rabbits demonstrated antimicrobial and antioxidant action against both bacteria tested, favoring the wound healing process. Considering the results, the use of fluid gel with 2% of clove powder (Syzigium aromaticum) based on the best antimicrobial, antioxidant and anti-inflammatory activities on healing of decubitus wounds (pododermatitis) of rabbits in commercial farming system.


Assuntos
Antibacterianos/farmacologia , Antioxidantes/farmacologia , Doenças do Pé/veterinária , Géis/uso terapêutico , Úlcera por Pressão/veterinária , Coelhos , Syzygium/química , Animais , Dermatite/etiologia , Dermatite/prevenção & controle , Dermatite/veterinária , Feminino , Doenças do Pé/etiologia , Doenças do Pé/prevenção & controle , Masculino , Extratos Vegetais/química , Extratos Vegetais/farmacologia , Úlcera por Pressão/etiologia , Úlcera por Pressão/prevenção & controle , Coelhos/lesões , Cicatrização
2.
Lett Appl Microbiol ; 72(1): 41-52, 2021 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-32910828

RESUMO

The use of rosemary essential oil (RO) and its combination with nisin (RO+N) in preventing the multiplication of Alicyclobacillus acidoterrestris in orange juice was evaluated. The minimum inhibitory and bactericidal concentrations (MIC and MBC) for RO were both 125 µg ml-1 while RO+N displayed a synergistic effect. The use of RO and RO+N at concentrations of 1, 4 and 8× MIC in orange juice for 96 h was evaluated in terms of their sporicidal effectiveness. With regard to the action against A. acidoterrestris spores, RO at 8× MIC was sporostatic, whereas RO+N at 1× MIC was sporicidal. Morphological changes in the structure of the micro-organism after treatment were also observed by microscopy. Furthermore, flow cytometric analysis showed that most cells were damaged or killed after treatment. In general, the antioxidant activity after addition of RO+N decreased with time. The results demonstrate that using the combination of RO and nisin can prevent the A. acidoterrestris growth in orange juice.


Assuntos
Alicyclobacillus/crescimento & desenvolvimento , Antibacterianos/farmacologia , Sucos de Frutas e Vegetais/microbiologia , Nisina/farmacologia , Óleos Voláteis/farmacologia , Rosmarinus/química , Alicyclobacillus/efeitos dos fármacos , Citrus sinensis
3.
Int J Clin Pract ; 53(6): 433-6, 1999 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-10622070

RESUMO

This open multicentre study compared the efficacy and tolerability of clarithromycin and spiramycin in the treatment of lower respiratory tract infections in Brazil and Colombia. A total of 125 patients with a clinical and radiological diagnosis of pneumonia, acute bronchitis or exacerbation of chronic bronchitis were randomised to receive oral doses of either clarithromycin (500 mg) or spiramycin (3 MIU) every 12 hours for courses of 5-10 days. Patients were assessed before the start of treatment, and at days 3-4 and days 9-17. Twenty-six (26) patients (16 in the spiramycin group and 10 in the clarithromycin group) reported adverse events, seven of whom withdrew from the trial. Statistical analysis detected no significant differences between efficacy (p = 0.768) or tolerability (p = 0.236) for the two treatment groups. Spiramycin therefore has similar efficacy to clarithromycin in the treatment of community-acquired lower respiratory tract infections.


Assuntos
Antibacterianos/uso terapêutico , Bronquite/tratamento farmacológico , Claritromicina/uso terapêutico , Pneumonia/tratamento farmacológico , Espiramicina/uso terapêutico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Doença Crônica , Infecções Comunitárias Adquiridas/tratamento farmacológico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...